The Divestment Challenge

Email: divestments@pharmaventures.com
Visit our website: https://www.pharmaventures.com/conten...

In this special edition of PharmaVentures Insights, we explore the challenges faced by pharmaceutical companies during the manufacturing divestment process, and how to accelerate the divestment process to achieve a successful outcome.

Paul Larsmon spoke with leading experts including:
Mark Bamforth, President and CEO, Arranta Bio
Stéphane Lepeu, Directeur Général Délégué / Chief Commercial Officer, DELPHARM
Jansen Jacob, Vice President, PharmaVentures

Talk to PharmaVentures

Before your next divestment programme, simply talk to our globally experienced M&A team, who will:
Demonstrate how our experience and depth of knowledge gained advising on over 40 site divestments globally can benefit you and your team
Connect you with the buyers actively looking for R&D or manufacturing operations within your space. PharmaVentures knows them and understands what they are looking for as well as the CDMO space they operate in
Discuss your business needs, any challenges you face, and how the proper process should be tailored for your company to ensure your site is divested safely
Provide you with any additional support you need, such as vital Valuation and Positioning expertise
Advise you on how to safeguard the security of supply and retain jobs to ensure consistent high-quality production continues
Support you through the complexities and manage the divestment process to provide extra resource as and when you need it to determine the right deal terms for the best return.

Contact us:
Mark Andrews​
Managing Director
Phone: +44 (0) 7951 204401

Jansen Jacob​
Vice President​
Phone: +44 (0) 7951 205 420

Email: divestments@pharmaventures.com
Visit our website: https://www.pharmaventures.com/conten...